Current approaches for the disease often copyright on shots of GLP-1 receptor activators, a procedure that can be inconvenient for individuals. Experts are actively pioneering innovative administration techniques to optimize patient adherence and results. These include by mouth formulations, inha… Read More

Viking Therapeutics has formed a mutually beneficial alliance with U.S. biopharmaceutical companies to develop and manufacture its GLP-1 drug candidate, VK2735. This marks a significant advancement in securing dependable production capabilities for these vital therapeutic agents. The agreement en… Read More